RPS6KB1 and metabolic dysfunction-associated steatotic liver disease: NAFLD pathogenesis is considered to be associated with the mammalian target of rapamycin (mTOR) signaling pathway [5].NAFLD is a manifestation of systemic insulin resistance, and mTOR and S6K1 are key components of the insulin signaling pathway [6, 7].